دورية أكاديمية
Imaging in rhabdomyosarcoma: a patient journey.
| العنوان: | Imaging in rhabdomyosarcoma: a patient journey. |
|---|---|
| المؤلفون: | de Vries ISA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Ewijk R; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Adriaansen LME; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands., Bohte AE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands., Braat AJAT; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands., Fajardo RD; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiotherapy, University Medical Centre Utrecht, Utrecht, the Netherlands., Hiemcke-Jiwa LS; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands., Hol MLF; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Otorhinolaryngology, University Medical Centre Utrecht, Utrecht, the Netherlands., Ter Horst SAJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands., de Keizer B; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands., Knops RRG; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Meister MT; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Schoot RA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Smeele LE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute (NCI), Amsterdam, the Netherlands.; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Scheltinga ST; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Vaarwerk B; Department of Paediatrics, Amsterdam UMC - Emma Children's Hospital, University of Amsterdam, Amsterdam, the Netherlands., Merks JHM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Rijn RR; Department of Radiology and Nuclear Medicine, Amsterdam UMC - Emma Children's Hospital, University of Amsterdam, Suite C1-423.1, Meibergdreef 9, 1105AZ, Amsterdam, the Netherlands. r.r.vanrijn@amsterdamumc.nl. |
| المصدر: | Pediatric radiology [Pediatr Radiol] 2023 Apr; Vol. 53 (4), pp. 788-812. Date of Electronic Publication: 2023 Feb 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0365332 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1998 (Electronic) Linking ISSN: 03010449 NLM ISO Abbreviation: Pediatr Radiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin, New York, Springer-Verlag. |
| مواضيع طبية MeSH: | Rhabdomyosarcoma*/diagnostic imaging , Rhabdomyosarcoma*/therapy , Sarcoma*/diagnostic imaging , Sarcoma*/therapy , Soft Tissue Neoplasms*/diagnostic imaging , Soft Tissue Neoplasms*/therapy , Soft Tissue Neoplasms*/pathology, Adolescent ; Child ; Humans ; Diagnostic Imaging ; Combined Modality Therapy |
| مستخلص: | Rhabdomyosarcoma, although rare, is the most frequent soft tissue sarcoma in children and adolescents. It can present as a mass at nearly any site in the body, with most common presentations in the head and neck, genitourinary tract and extremities. The optimal diagnostic approach and management of rhabdomyosarcoma require a multidisciplinary team with multimodal treatment, including chemotherapy and local therapy. Survival has improved over the last decades; however, further improvement in management is essential with current 5-year overall survival ranging from 35% to 100%, depending on disease and patient characteristics. In the full patient journey, from diagnosis, staging, management to follow-up after therapy, the paediatric radiologist and nuclear physician are essential members of the multidisciplinary team. Recently, guidelines of the European paediatric Soft tissue sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology (ESPR), in an ongoing collaboration with the International Soft-Tissue Sarcoma Database Consortium, provided guidance for high-quality imaging. In this educational paper, given as a lecture during the 2022 postgraduate ESPR course, the multi-disciplinary team of our national paediatric oncology centre presents the journey of two patients with rhabdomyosarcoma and discusses the impact on and considerations for the clinical (paediatric) radiologist and nuclear physician. The key learning points of the guidelines and their implementation in clinical practice are highlighted and up-to-date insights provided for all aspects from clinical suspicion of rhabdomyosarcoma and its differential diagnosis, to biopsy, staging, risk stratification, treatment response assessment and follow-up. (© 2023. The Author(s).) |
| التعليقات: | Erratum in: Pediatr Radiol. 2023 Mar 17;:. (PMID: 36930287) |
| References: | Ferrari A, Brecht IB, Gatta G et al (2019) Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110:120–126. https://doi.org/10.1016/j.ejca.2018.12.031. (PMID: 10.1016/j.ejca.2018.12.03130785015) Wyatt KD, Birz S, Hawkins DS, Minard‐Colin V, Rodeberg DA, Sparber‐Sauer M, Bisogno G, Koscielniak E, De Salvo GL, Ebinger M, Merks JH (2022) Creating a data commons: the international soft tissue sarcoma consortium (INSTRuCT). Pediatr Blood Cancer 69(11):e29924. https://doi.org/10.1002/pbc.29924. Martin-Giacalone BA, Weinstein PA, Plon SE, Lupo PJ (2021) Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility. J Clin Med 10. https://doi.org/10.3390/jcm10092028. Meister MT, Koerkamp MJAG, Souza T de, et al (2022) Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. 1–23. https://doi.org/10.15252/emmm.202216001. Gripp KW (2005) Tumor predisposition in Costello syndrome. American Journal of Medical Genetics - Seminars in Medical Genetics 137 C:72–77. https://doi.org/10.1002/ajmg.c.30065. Li H, Sisoudiya SD, Martin-Giacalone BA et al (2021) Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the children’s oncology group. J Natl Cancer Inst 113:875–883. https://doi.org/10.1093/jnci/djaa204. (PMID: 10.1093/jnci/djaa20433372952) Kratz CP, Rapisuwon S, Reed H et al (2011) Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157:83–89. https://doi.org/10.1002/ajmg.c.30300. (PMID: 10.1002/ajmg.c.303003086183) Kratz CP, Freycon C, Maxwell KN et al (2021) Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: an International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol 7:1800–1805. https://doi.org/10.1001/jamaoncol.2021.4398. (PMID: 10.1001/jamaoncol.2021.439834709361) Hartley AL, Birch JM, Marsden HB et al (1988) Neurofibromatosis in children with soft tissue sarcoma. Pediatr Hematol Oncol 5:7–16. https://doi.org/10.3109/08880018809031246. (PMID: 10.3109/088800188090312463155239) Shuman C, Beckwith BJ, Weksberg R (2000) Beckwith-Wiedemann Syndrome Synonym: Wiedemann-Beckwith Syndrome. [Updated 2016 Aug 11]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Bisogno G, de Salvo GL, Bergeron C et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma ( RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. https://doi.org/10.1016/S1470-2045(19)30617-5. (PMID: 10.1016/S1470-2045(19)30617-531562043) Bisogno G, Jenney M, Bergeron C et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19:1061–1071. https://doi.org/10.1016/S1470-2045(18)30337-1. (PMID: 10.1016/S1470-2045(18)30337-129941280) Schoot RA, Chisholm JC, Casanova M et al (2022) Metastatic rhabdomyosarcoma: results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 study and pooled analysis with the concurrent BERNIE Study. J Clin Oncol. https://doi.org/10.1200/jco.21.02981. (PMID: 10.1200/jco.21.02981357094129649279) Hibbitts E, Bradley JA, Rudzinski ER, et al (2019) Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors : a report from the Children ’ s Oncology Group. 6437–6448. https://doi.org/10.1002/cam4.2504. Gallego S, Zanetti I, Orbach D et al (2018) Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer 124:3201–3209. https://doi.org/10.1002/cncr.31553. (PMID: 10.1002/cncr.3155329797665) Bergeron C, Jenney M, de Corti F et al (2021) Embryonal rhabdomyosarcoma completely resected at diagnosis: the European paediatric Soft tissue sarcoma Study Group RMS2005 experience. Eur J Cancer 146:21–29. https://doi.org/10.1016/j.ejca.2020.12.025. (PMID: 10.1016/j.ejca.2020.12.02533567392) van Ewijk R, Schoot RA, Sparber-Sauer M et al (2021) European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of. Pediatr Radiol 51:1940–1951. https://doi.org/10.1007/s00247-021-05081-0. (PMID: 10.1007/s00247-021-05081-0341379368426307) Hawkins DS. Bisogno G, Koscielniak E (2023) Introducing INSTRuCT: An international effort to promote cooperation and data sharing. Pediatr Blood Cancer 7(3):e28701. Hawkins DS, Bisogno G, Koscielniak E (2020) Introducing INSTRuCT: an international effort to promote cooperation and data sharing. Pediatr Blood Cancer 1–2. https://doi.org/10.1002/pbc.28701. Jacobson JA, Middleton WD, Allison SJ et al (2022) Ultrasonography of superficial soft-tissue masses: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 304:18–30. https://doi.org/10.1148/radiol.211101. (PMID: 10.1148/radiol.21110135412355) Humphries PD, Sebire NJ, Siegel MJ, Olsen ØE (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848–854. https://doi.org/10.1148/radiol.2452061535. (PMID: 10.1148/radiol.245206153517951348) Fliedner FP, Engel TB, El-Ali HH et al (2020) Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. BMC Cancer 20:1–9. https://doi.org/10.1186/s12885-020-6617-x. (PMID: 10.1186/s12885-020-6617-x) Clemente EJI, Navallas M, de la Torre IBM et al (2020) Mri of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics 40:791–814. https://doi.org/10.1148/rg.2020190119. (PMID: 10.1148/rg.2020190119) Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026. (PMID: 10.1016/j.ejca.2008.10.02619097774) Schoot RA, McHugh K, van Rijn RR et al (2013) Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 269:870–878. https://doi.org/10.1148/radiol.13122607. (PMID: 10.1148/radiol.1312260723985275) Oliveira MP, de Lima PM, A, da Silva HJ, de Mello RJV, (2014) Neoplasm seeding in biopsy tract of the musculoskeletal system. A systematic review Acta Ortop Bras 22:106–110. (PMID: 10.1590/1413-7852201422020042224899866) Rogers T, Craigie R, Dall’igna P, Minard-colin V (2018) Surgery Guidelines Rhabdomyosarcoma European Paediatric Soft Tissue Sarcoma Study Group. European Pediatric Soft Tissue Sarcoma Study Group 1–18. Rogers TN, Seitz G, Fuchs J et al (2021) Surgical management of paratesticular rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 68:1–10. https://doi.org/10.1002/pbc.28938. (PMID: 10.1002/pbc.28938) World Health Organization (WHO) (2020) WHO classification of tumours: soft tissue and bone tumours , 4th ed. Lyon, France. Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 59:5–10. https://doi.org/10.1002/pbc.24118. (PMID: 10.1002/pbc.24118223786284008325) Ognjanovic S, Linabery A, Charbonneau G, Ross J (2009) Trends in childhood RMS incidence and survival in the US. Cancer 115:4218–4226. https://doi.org/10.1002/cncr.24465.Trends. (PMID: 10.1002/cncr.24465.Trends19536876) Rudzinski ER, Kelsey A, Vokuhl C et al (2021) Pathology of childhood rhabdomyosarcoma: a consensus opinion document from the Children’s Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 68:1–10. https://doi.org/10.1002/pbc.28798. (PMID: 10.1002/pbc.28798) Missiaglia E, Williamson D, Chisholm J et al (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30:1670–1677. https://doi.org/10.1200/JCO.2011.38.5591. (PMID: 10.1200/JCO.2011.38.559122454413) Williamson D, Missiaglia E, de Reyniès A et al (2010) Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28:2151–2158. https://doi.org/10.1200/JCO.2009.26.3814. (PMID: 10.1200/JCO.2009.26.381420351326) Haduong JH, Heske CM, Allen‐Rhoades W, Xue W, Teot LA, Rodeberg DA, Donaldson SS, Weiss A, Hawkins DS, Venkatramani R (2022) An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer 69(4):e29511. https://doi.org/10.1002/pbc.29511. Maurer HM, Crist W, Lawrence W et al (1988) The intergroup rhabdomyosarcoma study-I. A final report Cancer 61:209–220. https://doi.org/10.1002/1097-0142(19880115)61:2%3c209::AID-CNCR2820610202%3e3.0.CO;2-L. (PMID: 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L3275486) Beverly Raney R, Maurer HM, Anderson JR et al (2001) The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5:9–15. https://doi.org/10.1080/13577140120048890. (PMID: 10.1080/13577140120048890) Oberlin O, Rey A, Lyden E et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European Cooperative Groups. J Clin Oncol 26:2384–2389. https://doi.org/10.1200/JCO.2007.14.7207. (PMID: 10.1200/JCO.2007.14.7207184677304558625) Terwisscha van Scheltinga CEJ, Wijnen MHWA, Martelli H et al (2022) In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities: analysis of the EpSSG RMS 2005 study. Eur J Surg Oncol 48:1536–1542. https://doi.org/10.1016/j.ejso.2022.03.001. (PMID: 10.1016/j.ejso.2022.03.00135307252) Morris CD, Tunn PU, Rodeberg DA, et al (2020) Surgical management of extremity rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 1–8. https://doi.org/10.1002/pbc.28608. Li WJ, Chu ZG, Zhang Y et al (2019) Effect of slab thickness on the detection of pulmonary nodules by use of CT maximum and minimum intensity projection. Am J Roentgenol 213:562–567. https://doi.org/10.2214/AJR.19.21325. (PMID: 10.2214/AJR.19.21325) Samim A, Littooij AS, van den Heuvel-Eibrink MM et al (2017) Frequency and characteristics of pulmonary nodules in children at computed tomography. Pediatr Radiol 47:1751–1758. https://doi.org/10.1007/s00247-017-3946-2. (PMID: 10.1007/s00247-017-3946-2288713225693979) Vaarwerk B, Bisogno G, McHugh K et al (2019) Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma: are they clinically significant? A report from the European Paediatric Soft Tissue Sarcoma Study Group. J Clin Oncol 37:723–730. https://doi.org/10.1200/JCO.18.01535. Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-x. (PMID: 10.1007/s00259-014-2961-x25452219) Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 37:181–200. https://doi.org/10.1007/s00259-009-1297-4. (PMID: 10.1007/s00259-009-1297-419915839) Vali R, Alessio A, Balza R et al (2021) SNMMI procedure standard/EANM practice guideline on pediatric 18F-FDG PET/CT for oncology 1.0. J Nucl Med 62:99–110. https://doi.org/10.2967/jnumed.120.254110. (PMID: 10.2967/jnumed.120.254110333349128679588) Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257–1260. https://doi.org/10.1080/10428190903040048. (PMID: 10.1080/1042819090304004819544140) Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058. https://doi.org/10.1200/JCO.2013.53.5229. (PMID: 10.1200/JCO.2013.53.5229251137715015423) Ferrari A, Trama A, de Paoli A et al (2017) Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer 64:1–6. https://doi.org/10.1002/pbc.26348. (PMID: 10.1002/pbc.26348) Chisholm JC, Merks JHM, Casanova M et al (2017) Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer 83:177–184. https://doi.org/10.1016/j.ejca.2017.06.015. (PMID: 10.1016/j.ejca.2017.06.01528738258) Arndt CAS, Bisogno G, Koscielniak E (2018) Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 68:94–101. https://doi.org/10.1016/j.ctrv.2018.06.013. (PMID: 10.1016/j.ctrv.2018.06.01329940525) Rhee DS, Rodeberg DA, Baertschiger RM et al (2020) Update on pediatric rhabdomyosarcoma: a report from the APSA Cancer Committee. J Pediatr Surg 55:1987–1995. (PMID: 10.1016/j.jpedsurg.2020.06.01532674846) Casey DL, Mandeville H, Bradley JA et al (2022) Local control of parameningeal rhabdomyosarcoma: an expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatr Blood Cancer 69:1–10. https://doi.org/10.1002/pbc.29751. (PMID: 10.1002/pbc.29751) Ferrari A, Bergamaschi L, Chiaravalli S, et al (2022) Metastatic rhabdomyosarcoma: evidence of the impact of radiotherapy on survival. A retrospective single‐center experience. Pediatr Blood Cancer 1–8. https://doi.org/10.1002/pbc.29853. Palmer JD, Tsang DS, Tinkle CL, et al (2021) Late effects of radiation therapy in pediatric patients and survivorship. Pediatr Blood Cancer 68. https://doi.org/10.1002/pbc.28349. Buwalda J, Schouwenburg PF, Blank LECM et al (2003) A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur J Cancer 39:1594–1602. https://doi.org/10.1016/S0959-8049(03)00363-0. (PMID: 10.1016/S0959-8049(03)00363-012855267) Schoot RA, Slater O, Ronckers CM et al (2015) Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer 51:1424–1434. https://doi.org/10.1016/j.ejca.2015.02.010. (PMID: 10.1016/j.ejca.2015.02.01025998323) Schoot RA, Saeed P, Freling NJ, et al (2016) Local resection and brachytherapy for primary orbital rhabdomyosarcoma: outcome and failure pattern analysis. In: Ophthalmic Plastic and Reconstructive Surgery. Lippincott Williams and Wilkins, pp 354–360. Blank LECM, Koedooder K, Pieters BR et al (2009) The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head-and-neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys 74:1555–1562. https://doi.org/10.1016/j.ijrobp.2008.10.029. (PMID: 10.1016/j.ijrobp.2008.10.02919250759) Vaarwerk B, Hol MLF, Schoot RA et al (2019) AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma. Radiother Oncol 131:21–26. https://doi.org/10.1016/j.radonc.2018.10.036. (PMID: 10.1016/j.radonc.2018.10.03630773183) Chargari C, Haie-Meder C, Guérin F et al (2017) Brachytherapy combined with surgery for conservative treatment of children with bladder neck and/or prostate rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 98:352–359. https://doi.org/10.1016/j.ijrobp.2017.02.026. (PMID: 10.1016/j.ijrobp.2017.02.02628463154) Lautz TB, Martelli H, Fuchs J et al (2020) Local treatment of rhabdomyosarcoma of the female genital tract: expert consensus from the Children’s Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.28601. (PMID: 10.1002/pbc.28601327620047674210) Defachelles AS, Bogart E, Casanova M et al (2021) Randomized phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: a European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer. J Clin Oncol 39:2979–2990. https://doi.org/10.1200/JCO.21.00124. (PMID: 10.1200/JCO.21.0012434343032) van Ewijk R, Vaarwerk B, Breunis WB et al (2021) The value of early tumor size response to chemotherapy in pediatric rhabdomyosarcoma. Cancers (Basel) 13:1–15. https://doi.org/10.3390/cancers13030510. (PMID: 10.3390/cancers13030510) Dantonello TM, Stark M, Timmermann B et al (2015) Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma. Pediatr Blood Cancer 62:16–23. https://doi.org/10.1002/pbc.25207. (PMID: 10.1002/pbc.2520725263634) Ferrari A, Miceli R, Meazza C et al (2010) Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 28:1322–1328. https://doi.org/10.1200/JCO.2009.25.0803. (PMID: 10.1200/JCO.2009.25.080320124176) Oberlin O, Rey A, Sanchez De Toledo J et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr. J Clin Oncol 30:2457–2465. https://doi.org/10.1200/JCO.2011.40.3287. (PMID: 10.1200/JCO.2011.40.328722665534) Chisholm JC, Marandet J, Rey A et al (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29:1319–1325. https://doi.org/10.1200/JCO.2010.32.1984. (PMID: 10.1200/JCO.2010.32.198421357778) McHugh K, Roebuck DJ (2014) Review: Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer 61:3–6. https://doi.org/10.1002/pbc. (PMID: 10.1002/pbc24108532) Holme BM, Løberg M et al (2019) Revisiting surveillance schemes for cancer survivors. Ann Oncol 30:881–883. https://doi.org/10.1093/annonc/mdz107. (PMID: 10.1093/annonc/mdz10730895293) Shah M, Denlinger CS (2015) Optimal post-treatment surveillance in cancer survivors: is more really better? Oncology (Williston Park) 230–240. Jeffery G, Hickey B, Hider P (2002) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd002200. (PMID: 10.1002/14651858.cd00220012137642) Wille-Jørgensen P, Syk I, Smedh K et al (2018) Effect of more vs less frequent follow-up testing on overall and colorectal cancer–specific mortality in patients with stage II or III colorectal cancer the COLOFOL randomized clinical trial. JAMA - Journal of the American Medical Association 319:2095–2103. https://doi.org/10.1001/jama.2018.5623. (PMID: 10.1001/jama.2018.562329800179) Portman D (2018) Scanxiety. Fam Syst. Health 36:415. Bui KT, Liang R, Kiely BE, et al (2021) Scanxiety: a scoping review about scan-associated anxiety. BMJ Open 11. https://doi.org/10.1136/bmjopen-2020-043215. Vaarwerk B, Mallebranche C, Affinita MC et al (2020) Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer 126:823–831. https://doi.org/10.1002/cncr.32603. (PMID: 10.1002/cncr.3260331750944) Mindrup R (2022) Imprint of “Scanxiety.” AMA J Ethics 11:685–693. Fetzko S, Fonseca A, Frances Wedekind M, Gupta AA, Setty BA, Schraw J, Lupo PJ, Guillerman RP, Butala AA, Russell H, Nicholls L, Walterhouse D, Hawkins DS, Okcu MF (2022) Is detection of relapse by surveillance imaging associated with longer survival in patients with rhabdomyosarcoma? Pediatr. Hematol Oncol J 44(6):305–312. https://doi.org/10.1097/MPH.0000000000002429. (PMID: 10.1097/MPH.0000000000002429) Lin JL, Guillerman RP, Russell H v., et al (2013) Does routine imaging of patients for progression or relapse improve survival in rhabdomyosarcoma?Tumor. Pediatr Blood Cancer 63:202–205. https://doi.org/10.1002/pbc. FaR-RMS: an over-arching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma. ClinicalTrials.gov identifier: https://www.clinicaltrials.gov/ct2/show/NCT04625907 . Accessed 02 Feb 20223. World Health Orginazation (2005) Handbook for good clinical research practice (GCP): guidance for implementation. World Health Organization. Proton Technologies AG. Complete guide ti GDPR compliance. In: https://gdpr.eu/ . Accessed 26 Jan 2023. Kelly SM, Effeney R, Gaze MN et al (2022) QUARTET: a SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer. Eur J Cancer 172:209–220. https://doi.org/10.1016/j.ejca.2022.05.037. (PMID: 10.1016/j.ejca.2022.05.03735780527) QUARTET Project. In: https://siope.eu/activities/joint-projects/quartet/. Ferrari A, Orbach D, Sparber-Sauer M et al (2022) The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. Eur J Cancer 169:10–19. https://doi.org/10.1016/j.ejca.2022.03.028. (PMID: 10.1016/j.ejca.2022.03.02835490564) Ferrari A, Spunt SL, Sparber-Sauer M et al (2022) Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. Lancet Child Adolesc Health 6:221–223. https://doi.org/10.1016/S2352-4642(22)00036-0. (PMID: 10.1016/S2352-4642(22)00036-035176224) Wilkinson MD, Dumontier M, IjJ A et al (2016) Comment: the FAIR Guiding Principles for scientific data management and stewardship. Sci Data 3:1–9. https://doi.org/10.1038/sdata.2016.18. (PMID: 10.1038/sdata.2016.18) Davendralingam N, Sebire NJ, Arthurs OJ, Shelmerdine SC (2021) Artificial intelligence in paediatric radiology: future opportunities. British Journal of Radiology 94. https://doi.org/10.1259/bjr.20200975. |
| فهرسة مساهمة: | Keywords: Adolescent; Child; Medical oncology; Radiology; Rhabdomyosarcoma |
| تواريخ الأحداث: | Date Created: 20230227 Date Completed: 20230322 Latest Revision: 20230524 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10027795 |
| DOI: | 10.1007/s00247-023-05596-8 |
| PMID: | 36843091 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!